Presenting characteristics as predictors of duration of treatment in sarcoidosis

QJM: An International Journal of Medicine

Volumn 99, Issue 5, 2006, Pages 307-315

  Baughman, R P ^a,g   Judson, M A ^b   Teirstein, A ^c   Yeager, H ^d   Rossman, M ^e   Knatterud, G L ^f   Thompson, B ^f  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Clinical Trials & Surveys Corp   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; PENTOXIFYLLINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DYSPNEA; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT REFERRAL; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SEX DIFFERENCE; STANDARDIZATION; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION; VITAL CAPACITY;

EID: 33646249402     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl038     Document Type: Article

References (25)

1. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: An analysis of 818 patients. Q J Med 1983; 208:525-33.
2. Baughman RP, Lower EE. Treatment of sarcoidosis with corticosteroids: who is going to relapse and why? Sarcoidosis 1998; 15:19-20.
3. Reich JM, Johnson RE. Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years. Am J Med 1985; 78:61-7.
4. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111:623-31.
5. Johns CJ, Zachary JB, Ball WC. A ten year study of corticosteroid treatment of pulmonary sarcoidosis. Johns Hopkins Med 1974; 134:271-83.
6. Johns CJ, Michele TM. The clinical management of sarcoidosis: A 50-year experience at the Johns Hopkins hospital. Medicine 1999; 78:65-111.
7. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager HJ, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniack R, A Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885-9.
8. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr., McLennan G, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki BA, Weinberger SE, Knatterud GL, Chemiak R. Two year prognosis of sarcoidosis: The ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:204-11.
9. ACCESS Research Group. Design of a case controlled etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol 1999; 52:1173-86.
10. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr., the ACCESS Research group. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75-86.
11. Baughman RP, Drent M, Rizzato G, Judson MA, Nagai S. Proposed clinical phenotype of sarcoidosis. Am J Resp Crit Care Med 2003; 167:A170.
12. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133:97-103.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
14. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J 1961; 4:1165-72.
15. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149:893-8.
16. Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis 1998; 15:52-8.
17. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD. British Thoracic Society Sarcoidosis study: Effects of long term corticosteroid treatment. Thorax 1996; 51:238-47.
18. Johnston RN. Pulmonary sarcoidosis after ten to twenty years. Scott Med J 1986; 31:72-8.
19. Honeybourne D. Ethnic differences in the clinical features of sarcoidosis in South-East London. Br J Dis Chest 1980; 74:63-9.
20. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, the Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121:24-31.
21. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, Du BR, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP, ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:149-73.
22. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 1997; 18:853-64.
23. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: A systematic review. JAMA 2002; 287:1301-7.
24. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon R, Winget DB, Judson MA. The use of fluticasone for acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:198-204.
25. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 1997;14:121-30.